Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

AIM Price Correlated With Financials For AIM ImmunoTech

Free historical financial statements for AIM Immunotech Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 43 quarters since 2012. Compare with AIM stock chart to see long term trends.

AIM Stock Compared to Quarterly

AIM Income Statement

Revenue, Net:21000
Revenue Per Share:0.0004
Selling, General & Admin Expense:5170000
Research & Development Expense:1372000
Total Operating Expenses:6542000
Operating Income:-6521000
Net Income:-6385000
Earnings Per Share, Basic:-0.13
Shares Outstanding, Basic Avg:48082275

AIM Cash Flow

Operating Activities Net Income:
Net Cash from Operations:-4968000
Net Cash from Operations Per Share:-0.1033
Net Cash from Financing Activities:null
Net Cash from Investing Activities:250000
Net Change in Cash & Equivalents:-4693000

AIM Balance Sheet

Cash and Cash Equivalents:29759000
Short-Term Investments:6986000
Total Current Assets:41150000
Property, Plant & Equipment, Net:118000
Total Assets:46285000
Accounts Payable:957000
Total Short-Term Liabilities:2895000

Insider Trading

SEC Form 4
EQUELS THOMAS K.   CEO & President
161,291 sh at $0
RODINO III PETER W.   COO, Secretary, Gen. Counsel
80,646 sh at $0
80,646 sh at $0

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Vanguard Group Inc
1,987,595 sh
Morgan Stanley
1,398,449 sh
-200,855 sh
Blackrock Inc.
813,460 sh
-3,242 sh
Geode Capital Management, LLC
382,014 sh
State Street Corp
173,103 sh
Verition Fund Management LLC
153,002 sh
Bridgeway Capital Management Inc
151,000 sh
Renaissance Technologies LLC
124,908 sh
-303,163 sh
Price T Rowe Associates Inc /Md/
115,700 sh
-1,100 sh
Northern Trust Corp
86,517 sh
-2,190 sh
Cambridge Investment Research Advisors, Inc.
47,178 sh
500 sh
Seacrest Wealth Management, LLC
40,063 sh
Virtu Financial LLC
40,019 sh
-14,804 sh
Rockefeller Capital Management L.P.
40,000 sh
Raymond James Financial Services Advisors, Inc.
36,950 sh
-500 sh
Millennium Management LLC
29,352 sh
29,352 sh
Susquehanna International Group, Llp
28,981 sh
9,911 sh
Bank Of New York Mellon Corp
25,268 sh
ForthRight Wealth Management, LLC
20,000 sh
Lpl Financial LLC
15,982 sh
-500 sh
(1) Business

ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for
commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”).

Company’s primary present business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being
developed for globally important cancers, viral diseases and disorders of the immune system.

currently is proceeding primarily in three areas:

● Ampligen
plus Standard of Care (“SOC”) to treat pancreatic cancer patients, and in other
cancers, as a potential therapeutic that modifies the tumor microenvironment with the goal
of increasing anti-tumor responses to check point inhibitors and with SOC.

● Exploring
Ampligen’s antiviral activities and potential use as a prophylactic or treatment for
existing viruses, mutations thereof or new viruses.

● Ampligen
as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”)
and what we refer to as Post-COVID-19 Cognitive Impairment.

some two years after COVID-19 first appeared, the world has a number of vaccines and some promising therapeutics. AIM’s quest to
prove the antiviral activities of Ampligen continues. If Ampligen has the broad-spectrum antiviral properties that the Company believes
that it has, it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that
arise in the future. Unlike most developing therapeutics which attack the virus, Ampligen works differently. AIM believes that it activates
antiviral immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well.

N Injection is approved in Argentina for a category of sexually transmitted disease infections and patients that are not responsive or
are intolerant to recombinant interferon. Alferon N Injection is the only natural-source, multi-species alpha interferon currently approved
for sale in the United States for the intralesional treatment of refractory (i.e., resistant to other treatment) or recurring external
condylomata acuminata/genital warts in patients 18 years of age or older. Certain types of human papilloma viruses cause genital warts.
AIM also has approval from ANMAT for the treatment of refractory patients that failed or were intolerant to treatment with recombinant
interferon in Argentina.

Company recently announced the sale of its 30,000
sq. ft. facility at 783 Jersey
Ave, New Brunswick, N.J., where it conducts testing and has produced limited quantities of active pharmaceutical ingredients (“API”)
for its products. While the Company believes it has sufficient API to meet its current needs, it is also continually exploring new opportunities
to maximize its ability to fulfill future needs. AIM’s current and active produc

Data imported from AIM Immunotech Inc. SEC filings. Check original filings before making any investment decision.